JNM Podcast

Nuclear medicine’s greatest promise is improving patient’s lives, both in quality and longevity, and no one knows that more than patients who have had first-hand experience with nuclear medicine. In fact, it’s often the patients themselves that are our field's greatest advocates. From becoming ambassadors for nuclear medicine to championing FDA approvals of new radiopharmaceuticals to lobbyin...

Today the JNM Podcast is tackling an in-depth and technical topic: FDA approval pathways for new versions of current radiopharmaceuticals. Often called equivalents, the hope is that these “new” drugs can be expedited to the market by taking the same approval pathway of older, but similar versions. Joining host Ken Herrmann to help navigate these regulatory frameworks are two experts: Tom Hope, MD,...

When it comes to your health, it helps to have the full picture. That’s why total-body PET is such a critical development in medical science: in just one scan, total-body PET can capture every organ and its function from head to toe. This modality is especially helpful for patients with diseases like melanoma or rheumatoid arthritis, as well as various immunology studies that involve analyzing bon...

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.

Live from the 2026 SNMMI Annual Meeting in Los Angeles, California, with Johannes Czernin, MD, and Phillip J. Koo, MD.

Nuclear medicine is uniquely positioned at the intersection of diagnostics and therapeutics, so should it remain housed with imaging modalities, or stand alone as an independent specialty? Those against independence cite its commonalities with other specialties and the necessity of integrating nuclear medicine into more parts of patient care. Proponents cite the field's specialized workforce,...

A popular saying in the nuclear medicine field is that our work spans "from bench to bedside." But the path to get there isn't always clear. Even though there are constant breakthroughs in research and development, the cutting-edge treatments offered by nuclear medicine don't always make it to the patients who need it the most. Barriers within existing healthcare infrastructure...

Before we pop the champagne and count down to 2026, let’s take one last look back at 2025 through our favorite moments in nuclear medicine. Join host Ken Herrmann and his group of “JNM All-Stars:” Tom A. Hope, MD, Irene Buvat, PhD, and Jason S. Lewis, PhD, as they reminisce on their favorite parts of 2025. Tune in before the ball drops!

Data tells us that nuclear medicine has made extraordinary strides in curing prostate cancer, especially with the use of PSMA PET. But how are we reporting on PSMA, and how can this data be standardized globally? SPARC could be the answer! SPARC stands for "Standardized PSMA Reporting Criteria," and it's been initiated because of the widespread use and success of PSMA PET. These gui...

Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. In addition to staging and defining a disease, PET imaging can also give providers important information about what's going on in the body while a patient is undergoing their treatment regimen. PET can be used to adjust rad...

Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and mo...

Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show u...

In this live episode of The JNM Podcast, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories available in nuclear medicine.

The JNM Podcast is back and live from New Orleans. Guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?"

You love the column, now hear it in person! Throughout the meeting, JNM Editor in Chief Johannes Czernin will host Discussions with Leaders to talk about the most important and exciting topics in nuclear medicine. First up is Richard Wahl, MD.

Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients...

Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patien...

The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, w...